Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery and developer of Generex Oral-lyn™, the Company’s proprietary oral insulin spray product, announced today interim three-month results of a long-term six-month clinical trial performed in 24 adolescents and 5 young adult patients with Type-1 diabetes mellitus (DM). This data continuously showed that replacing just 1 one daily subcutaneous injection (s.c.) of regular insulin with Generex Oral-lyn™ during the day, improves parameters of metabolic control in the same manner observed with intensively monitored standard therapy.
